Nurix Therapeutics NRIX 深 滬
等待開盤 10-14 09:30:00 美东时间
9.72
-0.040
-0.41%
華盛通- 最 高9.905
- 今 開9.84
- 成交量 156.61万股
- 最 低 9.00
- 昨 收 9.76
- 總市值 7.43亿
- 52周最高 29.56
- 市盈率 靜 --
- 換手率 2.05%
- 52周最低 8.18
- 委 比 61.06%
- 總股本 7644.94万
- 歷史最高 52.38
- 量 比 1.21
- 振 幅 9.27%
- 歷史最低 4.22
- 每 手 1
- 風險率 5.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
Nurix三季度业绩不及预期
美股周五早盘，专注于靶向蛋白降解（TPD）疗法的临床阶段生物制药公司Nurix Therapeutics（NRIX）股价下跌7.5%，此前该公司公布第三季度...
10-10 23:03
Oppenheimer Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $28
Oppenheimer analyst Matthew Biegler maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $30 to $28.
10-10 20:26
Nurix Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.
Nurix Therapeutics shares are trading lower after the company reported worse-th...
10-10 04:19
Nurix And Gilead Advance IRAK4 Degrader GS-6791 Into Clinical Trials After Preclinical Results In Skin Disease
Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as part of the company's ongoing research collaboration with
09-17 19:10
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Nurix Therapeutics and Gilead Sciences have advanced GS-6791, a novel IRAK4 degrader, into clinical testing for inflammatory diseases. Preclinical data, presented at the EADV Congress, demonstrate GS-6791's ability to degrade IRAK4, inhibiting IL-1 and IL-36 responses and reducing disease in a model of atopic dermatitis. Serving as a potent, selective, and oral therapy, GS-6791 has shown promise in treating inflammatory conditions. The ongoing Ph...
09-17 11:00
Nurix Therapeutics to Discuss Bexobrutideg Developments
Nurix Therapeutics ( ($NRIX) ) has issued an update. Nurix Therapeutics announc...
09-03 20:29
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics announced that its executives will participate in several investor conferences in September, including the Wells Fargo Healthcare Conference, H.C. Wainwright Annual Global Investment Conference, RW Baird Healthcare Conference, Morgan Stanley Healthcare Conference, and Stifel Virtual Immunology & Inflammation Forum. The events will feature fireside chats and corporate presentations, accessible via the Investors section of Nurix'...
08-28 20:01
智翔金泰GR1802注射液启动过敏性鼻炎适应症III期临床试验
GENRIX BIO 8月13日，智翔金泰（股票代码：688443）发布公告，公司自主研发的GR1802注射液针对过敏性鼻炎适应症的II期临床试验已达到主要疗效...
08-13 17:05
6 Analysts Assess Nurix Therapeutics: What You Need To Know
6 analysts have expressed a variety of opinions on Nurix Therapeutics (NASDAQ:N...
08-01 05:00
